duplication event. Intragenic recombination events result in nucleotide deletions encompassing one or more exons and, sometimes, their flanking regions. These regions of identity misalign during meiosis to create new alleles and consequently lead to new variant proteins (for a review, see Daniels, 2013) .
The Gerbich blood group system [International Society of Blood Transfusion (ISBT) 020] is comprised of 12 antigens; 5 low-frequency and 7 high-frequency antigens (International Society of Blood Transfusion, 2008) . There are at least 3 variants with affected GPC expression and with or without co-expression of GPD that result in the loss of some highprevalence antigens (Walker & Reid, 2010) . The Yus (Yussef, GE:-2,3,4) and Gerbich (GE:-2,-3,4) phenotypes are the result of a deletion of exon 2 (GE*01.-02) and exon 3 (GE*01.-03) respectively. Another exceptional form, the Leach phenotype (GE:-2,-3,-4) with a complete absence of all GPC and GPD proteins, is due to the absence of exons 3 and 4 (GE*01N.01) or a missense mutation in the exon 3 (GE*01N.02) (International Society of Blood Transfusion, 2008; Daniels, 2013) . The malarial merozoite form of Plasmodium falciparum uses GPC and GPD as a receptor to invade human RBCs (Patel et al, 2001; Mayer et al, 2002) . Therefore, variants that alter the expression of exofacial domain probably arose from the natural selective pressure of the negative health effects of malaria (Maier et al, 2003) . Worldwide epidemiological studies have shown that variants of the Gerbich blood group system are observed in two major areas, Middle East/North Africa/Balkans, and Southeast Asia/Indonesia/Papua New Guinea. P. falciparum infestations are common in both of these areas (Mendis et al, 2001) .
Antibodies to Gerbich blood group antigens are important to consider in transfusion and pregnancy. The antibodies may be associated with haemolytic transfusion reactions and haemolytic disease of the newborn. Gerbich antibodies are particularly of clinical significance in pregnancy because they are often associated with a late-onset anaemia (Arndt et al, 2005) . The mechanism of this anaemia is similar to the one observed with antibodies to the Kell antigens (Denomme et al, 2006) . In vitro studies have shown that antibodies to glycophorin C inhibit growth of early erythroid progenitor cells by inducing mitochondrial depolarization and perturbing intracellular phosphorylation pathways; this leads to actin polymerization and the induction of caspase-independent apoptosis (Micieli et al, 2010) . This is consistent with the early expression of glycophorin C on erythroid progenitor cells during ontogeny. As a result, during pregnancy and postpartum, Gerbich antibodies not only cause classical macrophage-dependent erythroid cell destruction, but also inhibit early erythroid progenitor cell proliferation. The absence of reticulocytosis in haemolytic disease of the fetus and newborn due to Gerbich maternal antibodies is consistent with the effect on erythroid cell proliferation (Arndt et al, 2005) .
The anti-Gerbich antibodies are potentially clinically relevant and can cause haemolytic transfusion reactions (Baughn et al, 2011) . Alloimmunization among persons with the Yus and Gerbich phenotypes is complex. It appears that some individuals of the Gerbich phenotype make anti-Ge3 without anti-Ge2. Furthermore, the Gerbich phenotype (GE:-2,-3,4) seems to present with predominantly anti-Ge2 or anti-Ge3. However, antibodies found in the Yus phenotype (GE:-2,3,4) consistently show an anti-Ge2 specificity. The antibodies to the high-prevalence antigens are the most challenging to characterize. For Gerbich, no commercial antisera are available and antibody identification relies on rare red cells and alloantibodies shared among investigators. Sometimes these reagents are not as they appear and errors are made in the classification of new samples. Such antibody studies can benefit from samples that are well characterized at the molecular level to ensure identity between proband samples.
The nucleotide sequence homology between exons and flanking regions, together with deletion variant alleles, can make nucleotide interrogation (genotyping) for the prediction of blood group antigens a challenge. In addition, variation in the location of the deletion, i.e. the specific breakpoint of the deletion, can place the remaining information in a different context for mRNA processing and expression. We used a collection of alloimmunized individuals of the Yus and Gerbich phenotypes to characterize their nucleotide breakpoint regions in the corresponding GYPC alleles. We show that both the Yus and Gerbich phenotypes result from exon deletions due to a recombination event starting in either intron 1 (Yus phenotype) or intron 2 (Gerbich phenotype). Most importantly, a small set of different deletion mutant alleles was identified for each phenotype. We propose to classify these unique breakpoint 'deletion' alleles using a set of 'diagnostic' polymerase chain reactions to categorize the rare Yus and Gerbich phenotypes. Precise categorization will help understand the evolution of GYPC, provide nucleotide information that may impinge on expression, and assist with the search for similar variants for antigen-matched transfusions.
Materials and methods

Samples
Twenty-eight blood samples with a Yus or Gerbich phenotype from three blood transfusion services from Switzerland, Germany and France were investigated. Alloimmunization to Gerbich (CD236) antigens, and GYPC gene structure based on nucleotide sequencing were studied. The blood samples were from self-identified Caucasian individuals of Middle Eastern origin including Erythrea, Northern Africa (Maghreb area) and the Balkan region of South-East Europe. Included in this report is one genomic DNA sample from the Serum Cells and Rare Fluids (SCARF) repository (Judd, 2015) . Among the 28 blood samples analysed, 3 were collected in Z€ urich, Switzerland, 5 in Baden-Baden, Germany and 20 in Paris, France. Included in the analysis are 2 samples from Z€ urich who were parents (presumed carriers) of a Gerbich phenotype proband. A total of 60 Gerbich alleles were analysed; 56 from blood samples of the Yus or Gerbich phenotype, 2 of heterozygous carrier individuals and 2 from a reference Gerbich sample of the SCARF repository. The samples were not subject to informed consent authorization in accordance with the ethical committees of Switzerland. Samples from France and Germany were collected as clinical samples over time and patient/ blood donor identity was protected by blinding all respective data to all other study participants.
Phenotypic and serological investigations
Samples were tested for expression of Ge2 and Ge3. Standard manual tube and gel techniques for the indirect antiglobulin test were performed using sera derived from individuals previously alloimmunized from transfusion or pregnancy. Alloimmunization to Gerbich antigens was confirmed by the Institut National de la Transfusion Sanguine (INTS) (Paris) using standard reagent red cells, previously characterized Yus and Gerbich red cells and red cells available from a cryopreserved collection.
Positional PCR, Sanger sequencing, and diagnostic PCR-SSP Conventional and long-range high fidelity polymerase chain reactions for positional PCRs (Table SIA) were designed to evaluate genomic DNA for the presence or absence of specific sequences to locate potential GYPC nucleotide deletions. The final reaction volume of positional PCRs (Table SI A) and diagnostic PCRs (Table SID) was 10 ll and contained Ready PCR Buffer (Inno-train Diagnostik GmbH, Kronberg, Germany) and 0.4 units of AmpliTaq DNA polymerase (Applied Biosystems, Foster City, CA, USA). PCR products for sequencing (Table SI B) were amplified in 25-ll reactions as described above and sequenced using the primers (Table SI C) and standard Sanger sequencing procedures by Microsynth AG (Balgach, Switzerland). Cycling conditions for all positional PCRs and diagnostic PCRs were described previously (Crottet et al, 2014) . Cycling conditions for fragments between 1500 and 2800 base pairs in size were adapted as previously described (Gassner et al, 2005) . For fragments exceeding 4000 base pairs, the PCR Extender System from 5PRIME GmbH (Hilden, Germany) was used following the manufacturer's instructions. All in-house PCR procedures were performed on either GeneAmp PCR System 9700 or the Verity Dx automated thermocyclers (Applied Biosystems, Thermo Fisher Scientific, Life Science Group, Zug, Switzerland). PCR amplicons were visualized by agarose gel electrophoresis and documented by digital imaging.
PCR and BigDye Terminator sequencing (Sanger sequencing) were performed with the primers listed in Table SI B and C to confirm deletion breakpoints. Basic Local Alignment Search Tool (BLAST) algorithms from the National Center for Biotechnology Information (http://blast.ncbi.nlm.nih.gov/Bla st.cgi) were used to identify the positions of the 2 repeat regions within GYPC. The reference sequence NG_007479.1 was used throughout the report for nucleotide positions. Repeat region 1 represents 3608 base pairs, from nucleotide 36979 to 40586, and repeat region 2 represents 3587 base pairs, from nucleotide 40587 to 44173. An additional set of sequence-specific priming (SSP) PCR assays was designed to classify alleles (deemed 'diagnostic PCR-SSP') on the basis of the deletions characterized (Table SI D) . Primers and their concentrations are given in the supplemental information.
Results
Samples analyzed
Twenty-eight samples showed lack of expression of Ge2 or Ge3 antigens using a routine indirect antiglobulin test in the tube and gel techniques. Alloimmunization was detected in Table I Numbers marked with an asterisk (*) represent alleles that were sequenced to confirm the nucleotide breakpoints and one GETI allele. †anti-Ge2 or anti-Ge3 specificity not investigated.
GYPC Deletion Alleles
ª 2017 John Wiley & Sons Ltd 27 of 28 samples using either commercially available reagent red cells or thawed-deglycerolized Yus and Gerbich red cells from cryopreserved collections. One sample lacked information about the specificity of the antibody (anti-Ge2 or antiGe3). Two samples from parents of a proband (B-01412) analysed in Z€ urich were not alloimmunized, consistent with their presumed Gerbich deletion allele carrier status. AntiGe2 was observed in the sera of all samples with Yus deletion alleles (Table I) . Consistent with previous serological observations (Gourri et al, 2015) , anti-Ge2 or anti-Ge3 was demonstrated in all samples homozygous for Gerbich alleles.
Anti-Ge3 was not observed among the Yus deletion alleles (Table I ).
Molecular analysis of GYPC organization
The Yus and Gerbich deletion alleles characterized in this report are summarized in Table II . The 3 samples from Z€ urich identified 2 different deletion alleles, which we designated as Yus01 and Gerbich02, and each were homozygous for the respective deletion. The genomic deletion of the alleles was in line with the observed Yus or Gerbich phenotypes; Fig 2. Summary of the proportion of Yus and Gerbich deletion alleles observed in this report. The most frequent alleles are given in light grey (Yus01, Gerbich02), the least frequent alleles are given in white (Yus02, Gerbich01). Yus01 represents 66.7% of all Yus alleles observed in this study, Gerbich02 represents 90.0% of all Gerbich alleles observed in this study. Yus01 presents a deletion of exon 2 (GenBank accession LN901212), and Gerbich02 a deletion of exon 3 (LN901216). The parents of proband B-01412 were carriers of the deletion allele (Gerbich02) identified in their child. Three of the 5 samples from Baden-Baden were homozygous for either the Yus01 or Gerbich02 alleles identified in Z€ urich, as confirmed by positional PCR and Sanger sequencing. The remaining 2 samples were compound heterozygous for 2 new deletion alleles. One sample had 2 different Yus deletion alleles, Yus02 (LN901213) and Yus03 (LN901214), and the other sample had the previously observed Yus01 deletion allele and a new Yus04 allele (LN901215). The 20 Paris samples represented a collection of homozygous or compound heterozygous individuals carrying GYPC deletion alleles. Four of 20 samples were homozygous for Yus01 (N = 3) or Yus03 (N = 1), and 9 samples were homozygous for Gerbich02 (N = 8) or a new Gerbich03 deletion allele (N = 1) (LN901217). The remaining 7 samples represented compound heterozygotes for either Yus (N = 3) or Gerbich (N = 1) deletion alleles, including a previously reported Gerbich01 deletion allele (EF434170) (Scott & Easteal, 2008) , Yus plus Gerbich deletion allele (N = 2), or Yus plus a GETI-negative allele GE*01.-12 (LT605061) (N = 1) (Poole, 2008) . The proportions of the different Yus and Gerbich deletion alleles are summarized in Fig 2. The SCARF sample was unambiguously homozygous for the Gerbich02 deletion allele.
Characterization of GYPC deletions
Positional PCRs and targeted Sanger sequencing were used to characterize GYPC deletions (Table SI) . The location of the Yus and Gerbich deletions were identified relative to reference sequence NG_007479.1. On the basis of nucleotide polymorphisms between repeat region 1 and repeat region 2, the deletion of the 4 Yus deletion alleles overlapped by 1841 base pairs (nucleotides 39108 to 40948, on NG_007479.1) and comprised of 40 base pairs from the 3 0 region of intron 1 and 1744 base pairs from the 5 0 region of intron 2 (Fig 3) .
The deletion alleles each contained core 12-52 base pairs that could be assigned to either side of the breakpoint, e.g. identical sequences in either intron 1 or intron 2 and had a length of 3609, 3610, 3611 and 3607 base pairs for Yus01 to Yus04, respectively (Table II) . A similar pattern was observed for the 3 Gerbich deletion alleles. They all have their deletions overlapped with 2503 base pairs (40493 to 42995, on NG_007479.1) and were comprised of 2264 base pairs from the 3 0 region of intron 2 and 155 base pairs from the 5 0 region of intron 3 (Fig 3) . The Gerbich deletion alleles contained 23-74 base pairs that could be assigned to either intron 2 or intron 3 and had a length of 3587, 3585 and 3585 base pairs for Gerbich01 to Gerbich03, respectively (Table II) . We suggest that the ISBT Gerbich blood group system table be updated to subcategorize the Yus and Gerbich deletion alleles (Table III) .
PCR-SSP for Yus and Gerbich deletion allele genotyping
A set of 15 diagnostic PCR-SSP assays were designed for the unambiguous detection of all Yus and Gerbich deletion alleles. Eight diagnostic PCR-SSP assays were designed to identify the presence of specific wild-type sequences of GYPC including exons 2, 3 and 4, and 7 PCR-SSP assays were designed in order to be only positive for each deletion allele (Table IV) . The 15 diagnostic assays unambiguously recognized all homozygous and compound heterozygous genotypes, and made them clearly distinguishable from carriers with a wild-type allele in all cases. Representative ethidium bromide stained agarose gel electrophoresis images of PCR-SSP amplified fragments are shown in Figure S1 .
Discussion
GYPC is the gene responsible for the expression of both GPC and GPD, due to an alternate start codon in exon 2. There is a region of duplication or sequence homology between exon 2 and 3 and their flanking regions (repeat regions) of approximately 3600 base pairs each. These regions (Fig 1) are responsible for the emergence of exon deletion and Table IV . Interpretation matrices for diagnostic PCR using sequence-specific priming based assays to identify Yus and Gerbich deletion alleles.
Wild-type reactions
Yus allele reactions duplication alleles through non-homologous recombination events. The deletion alleles are found in endemic areas of Plasmodium falciparum including the Middle East countries and Papua New Guinea. Glycophorin C has been shown to bind the parasite EBA140 receptor (Maier et al, 2003) . In addition, murine embryonic stem cell studies have shown that deletion of glycophorin C confers resistance to RBC malaria parasite invasion (Yiangou et al, 2016) . Thus, the emergence of Gerbich variants is probably the result of selective pressure in endemic regions of Plasmodium falciparum. Subsequently, individuals expressing GYPC variants may become alloimmunized due to pregnancy or transfusion. We sought to evaluate the GYPC organization of deletion alleles of the Gerbich blood group system. The Yus phenotype is characterized by a deletion of exon 2 and flanking region. Without the genetic information for the alternate start codon, the deletion results in a truncated GPC protein and no expression of GPD, and RBCs from Yus deletion allele lack the Ge2 antigen. Alloimmunization to the highprevalence Ge2 antigen is possible. On the other hand, the Gerbich phenotype is characterized by a deletion of exon 3 and flanking region, responsible for the GE:-2,-3,4 phenotype. Surprisingly, the sera of these alloimmunized individuals can contain either anti-Ge2 or anti-Ge3. Apparently, a combination of both of these antibodies has not been reported. This phenomenon might be due to the immunodominance of the Ge2 antigen. For the Gerbich variant, earlier studies have shown that GPC and GPD are not present, as predicted by the deletion construct. However a variant form of the GPC protein is being expressed (Daniels, 2013) . It is not clear whether GPD.Gerbich is produced since exon 2 of the Gerbich allele possess the alternate start codon which could initiate the transcription of the GYPA mRNA that results in GPD.Gerbich protein, but may not for more than a few reasons. It is conceivable that the context of the start codon in deletion alleles may be lost or other critical intron sequence information might be missing. It has also been hypothesized that the GPD.Gerbich protein produced might not be correctly transported to the erythrocyte membrane or might be unstable and quickly degraded (Colin et al, 1989) .
Our study revealed that the Yus and Gerbich deletion alleles are defined by breakpoints that occur before or after exon 2, respectively. However, a plethora of breakpoints may be possible given the repetitive sequence flanking exons 2 and 3 is large. Currently, the Yus phenotype is defined by at least 4 deletion breakpoints. A similar observation is noted for the Gerbich phenotype, defined by 3 breakpoints after exon 2 and subject to deletions that include exon 3, and consequently lack the high-prevalence Ge3 antigen. Whether they express an altered form of GPD is presently unknown, and a subset of individuals (N = 4) had evidence of anti-Ge3 alloimmunization. The deletions associated with the Gerbich phenotype did not provide information to explain why individuals develop predominately anti-Ge2 or anti-Ge3. Our set of diagnostic PCRs defined all observed Yus and Gerbich deletion alleles and provided an innovative means to subcategorize the respective GE:-2,3,4 and GE:-2,-3,4 rare RBC phenotypes. It will thereby help with transfusion decisions, e.g. allow the transfusion of GE:-2,-3,4 phenotype to GE:-2,3,4 individuals, but not vice versa. The approach can identify heterozygous (carriers) of these deletion alleles, confirm fetal genotypes and resolve compound heterozygotes. Finally, the approach will prove useful in unravelling massive parallel sequence data involving deletion alleles of the Gerbich blood group system.
With the necessity to understand the similarities and differences among the GYPC deletion alleles Yus and Gerbich, we performed extensive positional PCR sequence analysis to identify the breakpoints. Then, we developed a set of diagnostic PCRs that can be used to classify both Yus and Gerbich phenotypic variants on the basis of their nucleotide deletion. The Yus phenotype was defined by 4 different breakpoints and the Gerbich phenotype by 3.
Conclusions
The extensive analysis and development of diagnostic molecular tools to define the Gerbich blood group system variants that lack the high-prevalence Ge2 and Ge3 antigens provide a reliable system for categorizing these antigens. The knowledge of the precise breakpoints for the most represented Yus and Gerbich deletion alleles presents the possibility to implement a direct and reliable search for the GE:-2,3,4 and GE:-2,-3,4 rare phenotypes in large populations using high-throughput red cell genotyping platforms. There is no clear distinction in the alloimmunization pattern among the Yus and Gerbich phenotypes on the basis of their breakpoint. However, although Gerbich phenotype individuals do not express Ge2 and Ge3, they do not always produce anti-Ge3 and more frequently develop anti-Ge2. This work further supports the original notion that the alternate start site in exon 2 is leaky (Cartron et al, 1990) , and therefore potentially subject to loss of utilization in some deletion alleles.
